Aref Salah, Abousamra Nashwa, El-Helaly Emann, Mabed Mohamed
Department of Clinical Pathology, Hematology Unit, Faculty of Medicine, Mansoura University, Egypt.
Hematology Unit, Oncology Center, Mansoura University, Egypt.
Asian Pac J Cancer Prev. 2020 Mar 1;21(3):743-748. doi: 10.31557/APJCP.2020.21.3.743.
Acute myeloid leukemia (AML) escape from immunosurveillance by immunosuppression. CD200 and CD56 expression represented an independent prognostic factor in many hematological malignancies but its importance in AML patients remains to be identified.
CD200 and CD56 expression were assessed in the bone marrow blasts for Fifty-two (52) newly diagnosed AML by flowcytometry before start of therapy.
CD200+ expression was reported in 28.8% of patients while 17.3% of patients showed CD56+ expression. M4 FAB revealed high frequency of both CD200+ and CD56+ expression. The overall survival of CD200+ patients was 19.2% compared to 35.3% in CD200- (P= 0.049). On the other hand, CD56+ patients had the lowest complete remission rate (22.2% vs. 53.4%). In addition, CD56+ population had significant bad influence on overall survival than those of CD56- population (11.1 % vs. 35.5 %, P= 0.047).
CD200 and CD56 positive expression by myeloblasts at diagnosis denote poor prognostic indicator and correlated with poor cytogenetic findings. CD200 could be used as therapeutic target in AML.
.
急性髓系白血病（AML）通过免疫抑制逃避免疫监视。CD200和CD56表达在许多血液系统恶性肿瘤中是独立的预后因素，但其在AML患者中的重要性仍有待确定。
在治疗开始前，通过流式细胞术对52例新诊断的AML患者的骨髓原始细胞进行CD200和CD56表达评估。
28.8%的患者报告有CD200+表达，而17.3%的患者显示CD56+表达。M4 FAB显示CD200+和CD56+表达的频率较高。CD200+患者的总生存率为19.2%，而CD200-患者为35.3%（P = 0.049）。另一方面，CD56+患者的完全缓解率最低（22.2%对53.4%）。此外，CD56+群体对总生存的不良影响比CD56-群体更显著（11.1%对35.5%，P = 0.047）。
诊断时原始粒细胞的CD200和CD56阳性表达表示预后不良指标，且与不良细胞遗传学结果相关。CD200可作为AML的治疗靶点。
